Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV (Human Immunodeficiency Virus) Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"

NCT04846946
View directory record Official record
Conditions
HIV Infections
Interventions
Hey, Friend
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 6:22 AM EDT
Completed No phase listed Observational

Consequences of Marijuana Use in HIV-infected Youth

NCT03927053
View directory record Official record
Conditions
Youth With HIV
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years to 28 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptation and Implementation of Project Encuentro in the U.S.-Mexico Border

NCT03293875
View directory record Official record
Conditions
HIV
Interventions
Community Events, Social Network HIV Testing, Peer Network Intervention
Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

The Getting Off App for Methamphetamine-Using Gay and Bisexual Men

NCT03884946
View directory record Official record
Conditions
Methamphetamine Abuse, HIV/AIDS
Interventions
Getting Off App
Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 6, 2026, 6:22 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

NCT05719441
View directory record Official record
Conditions
Acute HIV Infection
Interventions
VRC07-523LS, PGT121.414.LS, Placebo, ART
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

NCT00002231
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
APL 400-003
Biological
Lead sponsor
Wyeth-Lederle Vaccines
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men

NCT01751594
View directory record Official record
Conditions
HIV, AIDS
Interventions
MOVE Intervention, H4L Comparison Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Megace in HIV-Infected Women

NCT00002345
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 6, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 6, 2026, 6:22 AM EDT
Active, not recruiting No phase listed Observational

Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study

NCT04799483
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients

NCT00061256
View directory record Official record
Conditions
HIV Infections
Interventions
Alendronate, Calcium carbonate, Vitamin D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

NCT03913195
View directory record Official record
Conditions
HIV-1-infection
Interventions
ibalizumab-uiyk
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
10
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies

NCT00006075
View directory record Official record
Conditions
HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Evaluation of the Interaction Between Acetaminophen and Zidovudine

NCT00000731
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acetaminophen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
8
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 6:22 AM EDT
Not listed Phase 2 Interventional

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

NCT00225537
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
4-Methylumbelliferone (Heparvit®)
Drug
Lead sponsor
MTmedical Institute of Health
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

NCT00032669
View directory record Official record
Conditions
HIV Infections
Interventions
HAART
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

NCT00001020
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 6, 2026, 6:22 AM EDT
Not listed Phase 3 Interventional

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

NCT00008554
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
23
States / cities
Concord, California • Long Beach, California • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 6, 2026, 6:22 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates

NCT01378923
View directory record Official record
Conditions
Impulsive Behavior, Substance Abuse, HIV Risk Behavior, Anxiety, Depression, Criminogenic Thinking
Interventions
REVAMP, TAU
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 6, 2026, 6:22 AM EDT